CJC-1295
CJC-1295 with DAC (Drug Affinity Complex)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate natural growth hormone production from the pituitary gland. Its unique Drug Affinity Complex (DAC) modification allows it to bind to albumin, extending its half-life to 6-8 days and enabling sustained pulsatile growth hormone release. Unlike direct growth hormone therapy, CJC-1295 works with the body's natural rhythms to optimize anabolic effects while maintaining physiological hormone patterns.
Complete Research Database
Dual Receptor Mechanism (GIP/GLP-1)
GLP-1 Receptor Pathway
- •Increases insulin secretion (glucose-dependent)
- •Suppresses glucagon release
- •Slows gastric emptying
- •Enhances satiety in hypothalamus
- •Preserves beta-cell function
GIP Receptor Pathway
- •Enhances insulin secretion (stronger than GLP-1)
- •Promotes fat oxidation
- •Improves insulin sensitivity in muscle
- •Reduces hepatic glucose production
- •Modulates adipose tissue metabolism
Why Dual Agonism is Superior
CJC-1295 binds with high affinity to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells within the anterior pituitary gland, triggering a cascade of intracellular signaling that includes activation of adenylate cyclase, elevation of cyclic AMP (cAMP) levels, and subsequent activation of protein kinase A (PKA). This leads to pulsatile release of growth hormone in a physiologically relevant pattern, mimicking natural GHRH activity. The peptide's prolonged half-life, facilitated by its conjugation with a drug affinity complex (DAC) via a maleimide-linked lysine, enhances albumin binding in serum, extending its bioavailability to approximately 6-8 days. Downstream, it stimulates insulin-like growth factor 1 (IGF-1) production in the liver and peripheral tissues, promoting anabolic effects on muscle, bone, and fat metabolism without significantly upregulating other hormones like cortisol or prolactin.
Pharmacokinetic Profile
Top 10 High-Quality Research Articles
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
ReadGrowth hormone-releasing peptides and their analogs: structure-activity relationships and therapeutic applications
ReadMedical Disclaimer
CJC-1295 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings. Long-term effects are not well-studied in humans.